MarginsXMarginsX
Home › Markets › Health Care › STTK

Shattuck Labs Inc. (STTK)

STTK trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$4.66
+0.21% on the day
Market cap
$474.6M
Small cap
Revenue · 2025
$1.0M
-82.5% on 2024
Net income · 2025
-$48.8M
-4880.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1680367/000162828026014989/0001628280-26-014989-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerSTTK on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2020
SEC CIK0001680367

Financials · 2025

LineValue
Revenue$1.0M
Net income-$48.8M
Operating income-$51.5M
Net margin-4880.9%
Operating margin-5150.8%
Revenue growth-82.5%
Cash$54.2M
Total assets$91.0M
P/E (computed)Net income was not positive
P/S (computed)474.6×

Warning signs

Cash runway
15.0 months
$61.8M cash at September 30, 2026
Share count, 1 year
+60.9%
2025-10-23 to 2026-11-02 · +139.7% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$342K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$61.8M cash; operating cash flow -$12.4M a quarter.Report 2026-09-30
Shares outstanding101,842,552 (2026-11-02); 63,279,843 a year earlier; 42,485,485 three years earlier.Cover page 2026-11-02
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the marketLatest 2026-06-11
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, Austin, Texas, United StatesPCAOB Form AP 2026-03-30
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $250K, sold $592K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$0-$25.2M-$17.5M$61.8MNo debt tags$010-Q 2026-11-05
Q2 2026
2026-06-30
$0-$15.2M-$10.2M$63.3MNo debt tags$1.0M10-Q 2026-08-11
Q1 2026
2026-03-31
$0-$14.8M-$13.4M$90.4MNo debt tags$1.0M10-Q 2026-05-07
Q4 2025
2025-12-31
$0-$12.6M-$8.5M$54.2MNo debt tags$1.0M10-K 2026-03-05
Q3 2025
2025-09-30
$1.0M-$10.1M-$8.9M$42.5MNo debt tags$1.0M10-Q 2026-11-05
Q2 2025
2025-06-30
$0-$12.5M-$10.4M$50.5MNo debt tags$3.0M10-Q 2026-08-11
Q1 2025
2025-03-31
$0-$13.7M-$12.0M$60.9MNo debt tags$4.6M10-Q 2026-05-07
Q4 2024
2024-12-31
$0-$18.7M-$17.4M$57.4MNo debt tags$5.7M10-K 2026-03-05

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.

Price moves

WindowReturn
1 week+0.6%
1 month-15.3%
3 months-36.5%
Year to date+27.4%
1 year+152.7%
From 52-week high-42.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
AQSTAquestive Therapeutics Inc.$3.76-3.84%$472.6M
PHATPhathom Pharmaceuticals Inc.$5.88-2.97%$478.0M
OCSOculis Holding AG$7.63-0.13%$469.9M
LYELLyell Immunopharma Inc.$14.65+2.45%$469.0M
KMDAKamada Ltd.$8.11+0.25%$468.0M
NGNENeurogene Inc. Common Stock$23.30-2.63%$482.3M
CAPRCapricor Therapeutics Inc.$8.30-12.91%$482.6M
MNPRMonopar Therapeutics Inc.$71.97-0.04%$487.7M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier